Literature DB >> 15266629

Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.

Bernd C Kieseier1, Reinhard Kiefer, Ralf Gold, Bernhard Hemmer, Hugh J Willison, Hans-Peter Hartung.   

Abstract

During recent years, novel insights in basic immunology and advances in biotechnology have contributed to an increased understanding of the pathogenetic mechanisms of immune-mediated disorders of the peripheral nervous system. This increased knowledge has an impact on the management of patients with this class of disorders. Current advances are outlined and their implication for therapeutic approaches addressed. As a prototypic immune-mediated neuropathy, special emphasis is placed on the pathogenesis and treatment of the Guillain-Barré syndrome and its variants. Moreover, neuropathies of the chronic inflammatory demyelinating, multifocal motor, and nonsystemic vasculitic types are discussed. This review summarizes recent progress with currently available therapies and--on the basis of present immunopathogenetic concepts--outlines future treatment strategies.

Entities:  

Mesh:

Year:  2004        PMID: 15266629     DOI: 10.1002/mus.20076

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  40 in total

1.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

2.  Lesional accumulation of CD8(+) cells in sciatic nerves of experimental autoimmune neuritis rats.

Authors:  Zhi-Ming Zhang; Rongchen Shi; Hong Chen; Zhiren Zhang
Journal:  Neurol Sci       Date:  2015-09-26       Impact factor: 3.307

3.  Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies.

Authors:  Hubertus Köller; Michael Schroeter; Heinrich Feischen; Hans-Peter Hartung; Bernd C Kieseier
Journal:  J Neurol       Date:  2006-08-11       Impact factor: 4.849

Review 4.  Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.

Authors:  Ales Dudesek; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 5.  Therapy of immune neuropathies with intravenous immunoglobulins.

Authors:  Ralf Gold; Bernd C Kieseier
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

6.  Variants of Guillain-Barré syndrome: low incidence but high impact.

Authors:  Helmar C Lehmann; Hans-Peter Hartung
Journal:  J Neurol       Date:  2009-07-25       Impact factor: 4.849

Review 7.  Guillain-barré syndrome: modern theories of etiology.

Authors:  Todd A Hardy; Stefan Blum; Pamela A McCombe; Stephen W Reddel
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

Review 8.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

9.  Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome.

Authors:  Rong Kun Han; Yue Feng Cheng; Shan Shan Zhou; Hong Guo; Rui Dong He; Li Jun Chi; Li Ming Zhang
Journal:  J Clin Immunol       Date:  2013-11-12       Impact factor: 8.317

Review 10.  The role of chemokines in Guillain-Barré syndrome.

Authors:  Sharon Chiang; Eroboghene E Ubogu
Journal:  Muscle Nerve       Date:  2013-07-27       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.